Dexcom | DXCM - Ebitda

Aktienkurs
61.63
Täglich Wechseln
3.81 6.59%
Monatlich
0.65%
Jährlich
-27.90%
Q2 Prognose
60.39




Ebitda Veränderung Datum
Abbott USD 3.27B 178M 2025-12
Align Technology USD 260.87M 77.03M 2025-12
AtriCure USD 17.07M 2.79M 2026-03
Avanos Medical USD 13M 3M 2025-12
Baxter International USD -447M 873M 2025-12
Becton, Dickinson and Co. USD 1.71B 433M 2025-12
Boston Scientific USD 1.16B 213M 2025-12
Cooper Companies USD 323.4M 13.2M 2025-12
Dexcom USD 364.5M 57.7M 2026-03
Edwards Lifesciences USD 70.1M 394.2M 2025-12
Globus Medical USD 280.46M 27.86M 2025-12
Insulet USD 181.7M 12.3M 2026-03
Integra LifeSciences USD 76.18M 28.03M 2026-03
J&J USD 7.19B 2.32B 2025-12
Masimo USD 85.5M 6.4M 2026-03
Medtronic USD 2.93B 482M 2025-12
Merit Medical Systems USD 97.23M 17.69M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Solventum Corp USD 437M 0 2026-03
Stryker USD 1.57B 618M 2026-03
Tandem Diabetes Care USD 2.73M 30.17M 2026-03
Teleflex USD 247.07M 575.88M 2025-12
West Pharmaceutical Services USD 226.2M 7.7M 2026-03
Zimmer Biomet Holdings USD 759M 120.8M 2025-12